▪ Former CMO of Celgene where he presided over the registration of drugs including Abraxane, Revlimid, Vidaza, Istodax, and Taxotere

▪ Board member in various biotech companies including Transgene, Halozyme, Celator Pharmaceuticals, and CRO IDDI

▪ Author of more than 70 articles in peer-reviewed

▪ Senior advisor to the board of Quercis Pharma AG and Board Observer.

▪ M.D. from the University of the Republic (Uruguay) and Ph.D. from Collège de France

▪ Member of the National Academy of Science of Uruguay and of the Third World Academy of Science

▪ Former President of IIBCE Board of Directors

▪President of the National Council of Science and Technology between 2006-2009

▪ Professor of Medicine at Cornell Medical School and Chief of the Division of Hematology and Medical Oncology at Weill Cornell Medicine and New York-Presbyterian/Weill Cornell Medical Center

▪ Previously Clinical Director of the Rosenberg Clinical Cancer Center at Beth Israel Deaconess Medical Center, Harvard

▪ Member of the Board of PANCAN

▪ Author of more than 220 articles in the top tier peer-reviewed journals

▪ Professor at ETH Zürich heading the Responsive Biomedical Systems Lab

▪ Former researcher at MIT on nanosensors for in vivo tumour profiling

▪ Co-founder of MagnebotiX

▪Serial entrepreneur for more than 20 years. Started and successfully built/sold more than 10 companies

▪ Authored multiple drug patents and trademarks

▪ Has been studying naturally occurring small molecules as disease prevention agents with an emphasis on flavonoids for 20+ years

▪ Founded and built biotech/pharma business and bundled it into Quercis Pharma AG in 2019

▪ Doctor of Science (hc)

▪ Cardiologist and Former Minister of Health in France and Under-Secretary-General of the United Nations

▪ Founder of Unitlife and former chairman of the Executive Board of UNITAID

▪Chairman and CEO, Atanis Biotech AG

▪Prof. Emeritus at Harvard Medical School following 22 years of full professorship in Medicine

▪Immunologist, discovered Calcium Ion Channel

▪Managing Director of iXLife, a private investment fund with12 active healthcare investments

▪Board Member in Biotech and Big Pharma

▪ Former Chief Strategy Officer Vifor Pharma where he was driving the growth strategy, creating value through in-house development and a series of licensing deals & acquisitions.

▪ Board member in various biotech companies including 4TEEN4, Adrenomed and HICT

▪ 25+ years of experience as pharma executive at AMGEN and Vifor Pharma in commercial, strategic and R&D roles

▪Involved in selling VIFOR to CSL for $11.75Bn in December 2021

▪ Former Chairman of Quercis

▪ 25 years of experience in strategy consulting & investment management

▪ Partner and Managing Director at Cevian Capital for 12 years with 7 years at McKinsey’s Corporate Finance practice

▪ Seven years at McKinsey’s Corporate Finance practice, ultimately as Associate Principal

▪CEO of Spectrum Value Management

▪Board Member at Holcim, CANCON

▪Board member in various biotech companies including Transgene, Halozyme, Celator Pharmaceuticals, and CRO IDDI

▪Chairman of Scientific Advisory Board